DOCSLIB.ORG

Drug and Alcohol Abuse Prevention Biennial Review Report Or Contact Ms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug and Alcohol Abuse Prevention Biennial Review Report Or Contact Ms Drug-Free Schools and Communities Act 2019 Biennial Review (Academic Years 2017-2018 and 2018-2019) Appendix B Revised 08/26/2021 TABLE OF CONTENTS Overview 1 Introduction 2 Part One: Description of Programs 2 Drug/Alcohol Abuse Prevention Program for Students 3 Office of the Collegewide Dean of Student Engagement 3 Substance Abuse Prevention Education Events for Students 4 a. Takoma Park/Silver Spring Campus 4 b. Rockville Campus 5 c. Germantown Campus 7 Student Employment Services (SES) 9 Collegewide Athletics 9 SHaW Center Activities 10 Drug/Alcohol Abuse Prevention Program for Employees 12 Employee Education and Notification Procedures 12 Drug/Alcohol Education Presentations 13 Faculty Staff Assistance Program 13 Tip Sheets 13 New Employee Orientation 14 Staff Enrichment Day 14 Prevention of Workplace Violence Workshops 15 Employee Handbook 15 Part Two: Policy Statement, Notification Process, and Sanctions 15 Policy on Drug and Alcohol Abuse Prevention 15 Notification Procedure and Standards of Conduct for Employees 16 Standards of Conduct for Employees 16 Code of Conduct for Students 17 Local, State, and Federal Sanctions 18 Table 1 Federal Trafficking Penalties 19 Table 2 Federal Trafficking Penalties-Marijuana 20 An Overview of the More Common Offenses 20 Sanctions 22 Student Sanctions 22 Employee Sanctions 22 i TABLE OF CONTENTS (continued) Part Three: Health Risks 23 Health Risks of Drugs and Alcohol 23 Drugs’ Effects on the Body 23 Alcohol’s Effects on the Body 27 Part Four: Program Effectiveness 29 Analysis of Strengths and Weaknesses 29 Program Highlights Since 2017 Biennial Review 29 Student Program Progress 29 Statement of Goals 30 Recommendations for Program Revisions 30 Recommendations for Student Drug/Alcohol Abuse Prevention Program 30 The Office of Student Affairs Proposed Programs for the remainder of 2019 and 2020 31 The Office of Compliance, Risk and Ethics 31 The Office of Human Resources and Strategic Talent Management 32 Program Highlights Since 2017 Biennial Review 32 Employee Program Progress 32 Recommendations for Employee Drug/Alcohol Abuse Prevention Program Revisions 32 Appendices Appendix A: Drug-Free Schools and Campuses Appendix B: Disclosure Notifications a. Employees b. Students Appendix C: Tip Sheets Appendix D: Commonly Abused Drugs Appendix E: Alcohol and Cancer Risk Appendix F: Drugs of Abuse Certification Statement ii Overview Montgomery College actively ensures compliance with the Drug Free Schools and Campuses Regulations (34 CFR Part 86) of the Drug-Free Schools and Campuses (Appendix A). This requires the College to implement awareness and prevention programs regarding alcohol and drug use, abuse, and distribution by students and employees–across all three campuses located in Germantown, Rockville, and Takoma Park/Silver Spring, Maryland. In accordance to the regulations, this report outlines specific College efforts over the past two academic years– 2017- 2018 and 2018-2019. As required, we have reviewed our alcohol and other drug programs to determine compliance, effectiveness, and consistency of sanction enforcement. Additionally, we have determined appropriate and necessary changes to ensure program effectiveness. The results of this review are contained in this biennial report. Additionally, copies of the required annual notification pertaining to employees and students for all institutions of higher education are in (Appendix B). Representatives of Administrative and Fiscal Services, Student Affairs, Academic Affairs, and the Office of Compliance, Risk, and Ethics have conducted this 2019 Biennial Review. Please note the following representatives: 2019 Biennial Review Committee Members: • Ms. Maria Adams Davidson, Associate Compliance Specialist (Office of Compliance, Risk, and Ethics) • Dr. Monique Davis, Interim Dean of Instruction Health Sciences and Director of Nursing (Academic Affairs) • Ms. Rowena D’Souza, Human Resources Compliance Coordinator, Human Resources and Strategic Talent Management • Mr. Marvin Mills, Vice President for Facilities and Public Safety (Administrative and Fiscal Services) • Ms. Michelle Pagan, Executive Associate II (Administrative and Fiscal Services) • Ms. Nadine Porter, Associate Senior Vice President for Administrative and Fiscal Services • Mr. Adam Reid, Clery Act and Public Safety Manager (Administrative and Fiscal Services) • Dr. Clemmie Solomon, Collegewide Dean of Student Engagement and Takoma Park/Silver Spring Dean of Student Affairs For more information about this report contact: Montgomery College Office of Compliance, Risk, and Ethics 9221 Corporate Boulevard Rockville, MD 20850 240-567-7396 [email protected] 1 Introduction Founded in 1946, Montgomery College began as an evening college at Bethesda-Chevy Chase High School, serving an initial student body of just 186 students. By 1950, the College acquired the buildings and land previously occupied by the Bliss Electrical School. This Takoma Park location became the College’s first campus. The Rockville Campus opened in 1965 and the Germantown Campus opened in 1978. Today, the College is a multicampus institution that serves approximately 54,000 students annually through a combination of credit and noncredit continuing education programs. Chartered by the state of Maryland and governed by a 10-member Board of Trustees, Montgomery College is widely recognized for the quality and scope of its academic programs in liberal arts, humanities, sciences, business, and technologies. Campuses are located in Germantown, Rockville, and Takoma Park/Silver Spring, complemented by Workforce Development & Continuing Education centers and other off-campus sites throughout Montgomery County. Montgomery College offers degrees and certificates in 96 programs of study, which prepare students to earn an associate’s degree, transfer to a four-year college or university, enter the job market, upgrade career skills, complete an apprenticeship, or enhance life through enrichment experiences. Montgomery College faculty and staff are highly accomplished and innovative in providing individualized instruction and a supportive learning environment. Affordable tuition and various extracurricular activities—athletic programs, performing arts, student clubs and multicultural organizations, student government—create a complete college experience for the county’s culturally diverse student population. Courses and student services are provided year round for day, evening, and weekend students. The College is an open-access, public education institution dedicated to academic excellence and committed to student success. The College offers a wide range of postsecondary academic programs, career training, and lifelong learning opportunities at moderate cost to residents, businesses, and other organizations within Montgomery County. The College provides an enriching and comprehensive learning experience for students, faculty, staff, and community members who enhance the College with a diversity of ethnicities, cultures, ages, and experiences. This diversity offers opportunities for students to appreciate individual differences and to communicate ideas. As an educational resource center, the College acknowledges its responsibility and participates actively with public and private agencies to search for solutions to community problems. Part One: Description of Programs All students and employees share the responsibility for protecting the Montgomery College environment, and all are expected to exemplify high standards of professional and personal conduct. The illegal or abusive use of drugs or alcohol by students or employees adversely affects the educational environment. Montgomery College is committed to maintaining a learning environment that is free of illegal drug use and alcohol abuse. 2 In keeping with its primary purpose, Montgomery College will utilize educational strategies as its major approach to this problem. Everyone should be aware, however, that any student or employee who uses illegal drugs or abuses any drug, including alcohol, may be subject to prosecution and punishment by the civil authorities and to disciplinary proceedings by the College. Individuals who are using drugs should stop. This policy does NOT punish people who seek rehabilitation. All information provided by people who voluntarily avail themselves of drug or alcohol counseling or rehabilitation services will be confidential. It will NOT be used against the individual. With the passing of the Maryland Heroin and Opioid Education and Community Action Act of 2017, there are new requirements for policy development, prevention training, and reporting of overdose cases. In response to the policy requirement, Montgomery College has added the necessary language regarding heroin/opioid overdose prevention, response and reporting to our existing Policy 31005 and Procedure 31005CP–Drug and Alcohol Abuse Prevention. Also in compliance with this law all incoming full-time students must participate in heroin and opioid addiction and prevention awareness training and all part-time students be provided with resources concerning heroin/opioid abuse prevention and awareness. The law also requires designated employees to be trained in the administering of overdose-reversing medications (Naloxone). The Office of Public Safety has trained 65 officers in Naloxone administration since early 2017. Public safety officers who are trained in Naloxone administration may administer the medication to someone who has overdosed. To date, there have been
Load more

Recommended publications
  • Eluxadoline: a Treatment for IBS with Diarrhoea in Adults
    ■ NEW PRODUCT Eluxadoline: a treatment for IBS with diarrhoea in adults STEVE CHAPLIN Eluxadoline (Truberzi) KEY POINTS is an oral mixed opioid- receptor agonist/ ■ Eluxadoline is an opioid-receptor agonist/antagonist with low systemic absorption antagonist licensed for ■ It is licensed for the treatment of irritable bowel syndrome with diarrhoea in the treatment of irritable adults and is recommended by NICE as a second-line agent bowel syndrome with ■ The recommended dosage is 75–100mg orally twice daily diarrhoea in adults. ■ In clinical trials, response rates were 27%–31% with eluxadoline and 19.5% with placebo after 26 weeks’ treatment This article examines its ■ Common adverse effects include constipation, nausea and abdominal pain properties, efficacy in ■ Pancreatitis and sphincter of Oddi spasm were uncommon adverse events clinical trials and side- ■ Treatment with eluxadoline costs £88.20 per month. effects. he initial management of irritable locally within the gastrointestinal tract, Tbowel syndrome (IBS) entails dietary slowing gastrointestinal transit, reducing and lifestyle change and treatment with urgency and improving stool consistency; antispasmodic agents.1 For people with its abuse potential is low. IBS and diarrhoea, loperamide is the anti- Eluxadoline is licensed for the treat- motility agent of first choice, adjusting the ment of IBS with diarrhoea in adults. The dose to achieve optimum stool consist- recommended dosage is 100mg twice ency. If this is unsatisfactory, treatment daily (reduced to 75mg twice daily if with a low-dose tricyclic antidepressant poorly tolerated). Treatment should be should be considered, with an SSRI a initiated at the lower dose in older people further option if this is unsuccessful.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • Tobacco Labelling -.:: GEOCITIES.Ws
    Council Directive 89/622/EC concerning the labelling of tobacco products, as amended TAR AND NICOTINE CONTENTS OF THE CIGARETTES SOLD ON THE EUROPEAN MARKET AUSTRIA Brand Tar Yield Nicotine Yield Mg. Mg. List 1 A3 14.0 0.8 A3 Filter 11.0 0.6 Belvedere 11.0 0.8 Camel Filters 14.0 1.1 Camel Filters 100 13.0 1.1 Camel Lights 8.0 0.7 Casablanca 6.0 0.6 Casablanca Ultra 2.0 0.2 Corso 4.0 0.4 Da Capo 9.0 0.4 Dames 9.0 0.6 Dames Filter Box 9.0 0.6 Ernte 23 13.0 0.8 Falk 5.0 0.4 Flirt 14.0 0.9 Flirt Filter 11.0 0.6 Golden Smart 12.0 0.8 HB 13.0 0.9 HB 100 14.0 1.0 Hobby 11.0 0.8 Hobby Box 11.0 0.8 Hobby Extra 11.0 0.8 Johnny Filter 11.0 0.9 Jonny 14.0 1.0 Kent 10.0 0.8 Kim 8.0 0.6 Kim Superlights 4.0 0.4 Lord Extra 8.0 0.6 Lucky Strike 13.0 1.0 Lucky Strike Lights 9.0 0.7 Marlboro 13.0 0.9 Marlboro 100 14.0 1.0 Marlboro Lights 7.0 0.6 Malboro Medium 9.0 0.7 Maverick 11.0 0.8 Memphis Classic 11.0 0.8 Memphis Blue 12.0 0.8 Memphis International 13.0 1.0 Memphis International 100 14.0 1.0 Memphis Lights 7.0 0.6 Memphis Lights 100 9.0 0.7 Memphis Medium 9.0 0.6 Memphis Menthol 7.0 0.5 Men 11.0 0.9 Men Light 5.0 0.5 Milde Sorte 8.0 0.5 Milde Sorte 1 1.0 0.1 Milde Sorte 100 9.0 0.5 Milde Sorte Super 6.0 0.3 Milde Sorte Ultra 4.0 0.4 Parisienne Mild 8.0 0.7 Parisienne Super 11.0 0.9 Peter Stuyvesant 12.0 0.8 Philip Morris Super Lights 4.0 0.4 Ronson 13.0 1.1 Smart Export 10.0 0.8 Treff 14.0 0.9 Trend 5.0 0.2 Trussardi Light 100 6.0 0.5 United E 12.0 0.9 Winston 13.0 0.9 York 9.0 0.7 List 2 Auslese de luxe 1.0 0.1 Benson & Hedges 12.0 1.0 Camel 15.0 1.0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Special Report from Oil and Gas Investor and Global Business Reports
    Mexico A Special Report From Oil and Gas Investor and Global Business Reports Photo courtesy of Nabors. MEXICO OIL AND GAS Mexico’s Energy Reform: an opportunity in three generations Mexico’s oil production has decreased from 3.4 MMbbl/d in 2004 to 2.4 MMbbl/d today. Photo courtesy of Pemex. onday August 11,, 2014, represented historic mo- ation was not sustainable; a steep decrease in oil prices over ment for Mexico: President Enrique Peña Nieto, the second half of 2014 has only helped the cause of those M who brought the Institutional Revolutionary Par- advocating for the reform. “What closes the circle of the re- ty (PRI) back into power in 2012, signed the Energy Reform form is that, although the Mexican state will no longer keep bill after the legislative powers approved the secondary laws 100% of the oil income, total revenues from the hydrocar- that will develop the new framework. bons sector will increase because production volumes will be By the end of October, the details of the 25 sets of rules higher,” explained Fluvio César Ruiz Alarcón, independent transforming the country’s model for the oil and gas and board member of Pemex. electricity sectors had already been published by the Mexi- The expectation is to reach 3 MMbbl/d by 2018, al- can administration. The process is developing at quite a fast though Ruiz Alarcón believes that timing to be overambi- pace considering that this is landmark reform that involves tious: “To add production to a 76-year-old structure will constitutional change and ends the 76-year monopoly in ex- take longer,” he said.
    [Show full text]
  • Federal Controlled Substances Checklist
    Federal Controlled Substances Checklist Introduction By Norton Tooby & Joseph Justin Rollin We have reprinted here an alphabetical list of all controlled substances forbidden under federal drug laws, taken from the official website of the U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, at http://www.justice.gov/dea/pubs/scheduling.html. No copyright is asserted to this information. This list changes frequently. The official list is contained at 21 CFR § 1308, as supplemented by final rules published in the Federal Register. The attached checklist of controlled substances has been compiled into one list, and placed in alphabetical order, for ease of reference. If a controlled substance is listed in the federal drug schedules, it triggers deportation, INA § 237(a)(2)(B)(i), 8 U.S.C. § 1227(a)(2)(B)(i), and inadmissibility. INA § 212(a)(2)(A)(i)(II), 8 U.S.C. § 1182(a)(2)(A)(i)II). In addition, there is an aggravated felony defined as illicit trafficking in a controlled substance. INA § 101(a)(43)(B), 8 U.S.C. § 1101(a)(43)(B). The same controlled substance lists apply to this ground of deportation as well. If a drug is not listed on the federal controlled substances schedules, it does not trigger removal under these grounds. In addition, because the government has the burden of proof in deportation removal proceedings by clear and convincing evidence, if the record of conviction is ambiguous as to whether the specific substance involved in the particular case was listed on the federal schedules, the government cannot obtain a deportation removal order on this ground.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]